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Initial results: Doses measured by TLD were
on average by 4% lower than doses pre-
calculated using the modified algorithm. Mean
doses normalized to those pre-calculated and
their standard deviations (both in per cents)
were respectively: 96.1 % and 0.4 % for
phantom with diameter of 20; 96.5% and
0.7% for diameter of 30 cm and 96.0% and
0.8% for diameter of 40 cm.
Conclusions: Measured doses proved
correctness of elaborated algorithm. Very low
standard deviations are resulting from regular
cylindrical shape of the phantoms.
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Introduction: RT plays an important role in
the management of LABC, yet clinical outcomes
still remain far from satisfactory. The aim of this
study was to evaluate retrospectively factors
determining local control in a large series of
consecutive LABC pts managed with RT as the
primary locoregional treatmenł.
Material and methods: The records of 261
primarily inoperable LABC pts treated between
1991 and 1997 at two institutions: Medical
University of Gdansk, Poland and Velindre NHS
Trust, Cardiff, UK were analysed. Ali pts
received megavoltage RT to the breast with two
tangential fields, and the adjacent Iymph node
areas were irradiated using customised fields.
Due to a large scale of RT doses and
fractionation schedules, normalised total dose
(NTD) was calculated for all patients using a
linear quadratic model. In 241 pts RT constituted
the only local treatment and the remaining 20
pts were subsequently subjected to
mastectomy. Most pts received chemotherapy
and/or endocrine therapy prior or after RT.
Results: Within the median follow-up of 37
months, locoregional recurrence occurred in 95
of 251 evaluable pts (38%). Three-year and five-
year locoregional-free survival rates were 59%
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and 48%, respectively. At multivariate analysis
of variabies predicting the risk of locoregional
relapse, inflammatory carcinoma (p<0.01; RR
2.1), T4 disease (p<0.01; RR 2.9) and
involvement of supraclavicular Iymph nodes
(p<0.01; RR 2.4) were the most significant
clinical factors, whereas response to RT
(p<0.01; RR 1.2) and NTD (p<0.01; RR 0.7)
were the most important therapeutic factors.
Increasing the total dose to the tumour by 10 Gy
was associated with 30% reduction of local
relapse.
Conclusions: Due to large heterogeneity of
LABC pts, judicious tailoring of RT, particularly
in terms of dose prescribing, is essential to
increase the chance of locoregional cure.
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Aim: to discuss some problems of the
"conventionality" in the prospective and
retrospective studies finished last year at the RT
Department in Warsaw. The phase III c1inical
trial. The study was conducted according to the
evidence based rules. Cancer of the larynx -
glottis and supraglottis T1 - T3 NO MO WHO O-
1, 395 cases 196 in experimental, 199 in
conventional arm. The retrospective study
concerned all patients with the cancer of larynx
treated radically in the II department in years
1989 to May 1995. 372 patients T1- T4, N1-N3,
MO. The prospective material 150 patients were
selected [age 75 and less, WHO 0-1, T1-T3, NO,
MO] employing the same selection criteria as in
the prospective study. The comparison was
performed with the conventional arm of the
clinical trial [199 cases].
Results of the study: Significant differences
were recorded in the: ? performance status and
in the number of T1 and T3 cases, ? compliance
to protocol in the total dose and the overall
treatment time, ? response to treatment in the
whole group and in the particular stages These
results indicate the very demanding selection of
cases and much more rigorous compliance with
the therapeutic protocol in the prospective study.
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